A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer

PURPOSE: Seviteronel is an orally-administered selective cytochrome P450c17a 17,20-lyase and androgen receptor inhibitor with anti-tumor activity in vitro and in vivo, and clinical activity in men with advanced castration-resistant prostate cancer (CRPC) and men and women with advanced breast cancer...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Chemother Pharmacol
Main Authors: Peer, Cody J., Schmidt, Keith T., Kindrick, Jessica D., Eisner, Joel R., Brown, Victoria V., Baskin-Bey, Edwina, Madan, Ravi, Figg, William D.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8132106/
https://ncbi.nlm.nih.gov/pubmed/31367790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03908-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items